![]() ![]() The company's weight-loss treatments, although not yet approved, look superior to Novo Nordisk's drugs. The strong need for chronic weight management and obesity care suggests that both Eli Lilly and Novo Nordisk can generate significant growth with their respective weight-loss treatments.īut if I were picking a winner, it would be Eli Lilly. Ozempic, Wegovy, and to a lesser extent Saxenda are names that have become synonymous with weight loss, and their rising popularity on social media could give Novo Nordisk an advantage over Eli Lilly's weight-loss treatments, which still need FDA approval. Earlier this year, the company said it would be investing $2.3 billion to increase its production capacity to help alleviate these shortfalls in the future. Shortages of Wegovy and Ozempic have led to consumers using Saxenda, which is a less popular weight-loss option, but the company says even that is in short supply. Novo Nordisk's biggest problems these days are related to its simply not having enough capacity to meet demand. Ozempic, which isn't yet approved for weight loss but has nonetheless showed effectiveness in helping people trim their weight, also brought in 63% more in revenue during the period. Through the first three months of the year, the company's obesity care sales more than doubled to 7.8 billion Danish krone ($1.2 billion), with sales of Wegovy tripling and Saxenda's revenue rising by 64%. The advantage Novo Nordisk has over Eli Lilly right now is that it already has multiple weight-loss products approved for that use. With multiple high-performing weight-loss treatments in its portfolio, there's plenty of reason to be bullish on Eli Lilly being the big name in weight loss in the future. Patients taking the drug lost up to 24% of their weight after taking the treatment for close to a year. ![]() That compares favorably with Ozempic and Wegovy, Novo Nordisk's flagship drugs, on which people have experienced weight loss closer to around 15%.īut what's even more promising is that Eli Lilly has a potentially more attractive obesity treatment in retatrutide. But shedding pounds is something it has shown to be quite proficient at doing.ĭata from clinical trials last year found that Mounjaro helped people lose as much as 22.5% of their body weight. If it's successful at helping people lose weight, it could be useful in treating many other obesity-related illnesses, and therein lies the big opportunity for the drug in the long run, as it could go beyond just strictly helping people shed pounds. Mounjaro has been such an exciting drug that some analysts think it can even generate a whopping $100 billion at its peak. ![]() Mounjaro is a diabetes drug that isn't approved to treat weight loss, but that may soon change the Food and Drug Administration (FDA) has granted it a fast-track designation, and it may get approval for the indication by the end of the year. Eli Lilly has some encouraging weight-loss treatments in its portfolio. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |